Palifermin biosimilar - Genemen Biotech

Drug Profile

Palifermin biosimilar - Genemen Biotech

Alternative Names: Lyophilised recombinant human keratinocyte growth factor - Genemen Biotech

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Genemen Biotech
  • Class Chemoprotectants; Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Stomatitis

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stomatitis(In volunteers) in China (IV, Injection)
  • 07 Jan 2013 Phase-I clinical trials in Stomatitis (in volunteers) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top